Tardive dyskinesia: Deterioration of symptoms · patients with antipsychotic‐induced tardive dyskinesia
VITAMIN E may leads to lower tardive dyskinesia: 3. Deterioration of symptoms compared with PLACEBO (low certainty).
1 finding from 1 review
Adverse effect: any · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether VITAMIN E changes adverse effect: any compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether VITAMIN E changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Cognitive subdomain: episodic memory measured at the end of · MCI
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low
Executive functioning · MCI
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low
Quality of life ‐ not measured · MCI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · MCI
1 finding from 1 review
no estimate extracted
1 study · 1 participants
GRADE not reported
Incidence of dementia due to Alzheimer's disease · MCI
1 finding from 1 review
Cognitive function · MCI
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low
Any AMD · general population
Vitamin E showed no clear difference in any AMD compared with placebo (high certainty).
1 finding from 1 review
Progression to late AMD (neovascular AMD, geographic atrophy or both) · general population
Vitamin E showed no clear difference in late AMD (either neovascular AMD or geographic atrophy or both) compared with placebo (moderate certainty).
1 finding from 1 review
Neovascular AMD · general population
It is very uncertain whether vitamin E changes neovascular AMD compared with placebo (very low certainty).
1 finding from 1 review
Geographic atrophy · general population
It is very uncertain whether vitamin E changes geographic atrophy compared with placebo (very low certainty).
1 finding from 1 review
Quality of life · general population
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects (AE) · general population
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Resource use and costs · general population
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Vitamin D insufficiency: 25‐OH vitamin D < 50 nmol/L · term breastfed infants to prevent vitamin D deficiency and improve bone health
It is very uncertain whether vitamin D given to infants changes vitamin D insufficiency: 25‐OH vitamin D < 50 nmol/L compared with vitamin D given to lactating mothers (very low certainty).
1 finding from 1 review
Vitamin D deficiency: 25‐OH vitamin D < 30 nmol/L · term breastfed infants to prevent vitamin D deficiency and improve bone health
It is very uncertain whether vitamin D given to infants changes vitamin D deficiency: 25‐OH vitamin D < 30 nmol/L compared with vitamin D given to lactating mothers (very low certainty).
1 finding from 1 review